Evidence map›Paper›PMID 37715924›Full record

ReviewNeuroscience bulletin2024

Brain Pathology in COVID-19: Clinical Manifestations and Potential Mechanisms.

Zhixing Xu, Hui Wang, Siya Jiang, Jiao Teng, Dongxu Zhou, Zhong Chen, Chengping Wen, Zhenghao Xu

Open access · greenAbstract readReview
In one paragraph

Review in Neuroscience bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Neurological, psychological, psychosocial complications of long-COVID and their management.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  6. Neurological complications caused by SARS-CoV-2.Clinical microbiology reviews · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhixing XuFirst School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Hui WangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Siya JiangSecond School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Jiao TengAffiliated Lin'an People's Hospital of Hangzhou Medical College, First People's Hospital of Hangzhou Lin'an District, Lin'an, Hangzhou, 311300, China.
Dongxu ZhouSchool of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Zhong ChenSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Chengping WenLaboratory of Rheumatology and Institute of TCM Clinical Basic Medicine, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China. wengcp@163.com.
Zhenghao XuKey Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China. xuzhenghao@zcmu.edu.cn.ORCID http://orcid.org/0000-0003-0033-525X
Zhejiang Chinese Medical University · CNHangzhou First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurological manifestations of coronavirus disease 2019 (COVID-19) are less noticeable than the respiratory symptoms, but they may be associated with disability and mortality in COVID-19. Even though Omicron caused less severe disease than Delta, the incidence of neurological manifestations is similar. More than 30% of patients experienced "brain fog", delirium, stroke, and cognitive impairment, and over half of these patients presented abnormal neuroimaging outcomes. In this review, we summarize current advances in the clinical findings of neurological manifestations in COVID-19 patients and compare them with those in patients with influenza infection. We also illustrate the structure and cellular invasion mechanisms of SARS-CoV-2 and describe the pathway for central SARS-CoV-2 invasion. In addition, we discuss direct damage and other pathological conditions caused by SARS-CoV-2, such as an aberrant interferon response, cytokine storm, lymphopenia, and hypercoagulation, to provide treatment ideas. This review may offer new insights into preventing or treating brain damage in COVID-19.

Indexed as

COVID-19StrokeBrainHumansSARS-CoV-2BrainCOVID-19Neurological pathologySARS-CoV-2

Identifiers

PMID37715924
PMCPMC10912108
OpenAlexW4386803496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.